Table 2.

Time to clinically meaningful response for patients on the seven most frequently used drugs (independently or in combination with other treatments)

Treatment (N)	N studies	N patients	% of patients on drug extractable TCMR	Mean (SD) TCMR	Standard error
Antivirals for systemic use
Lopinavir/ritonavir
Total	15	76	3.8%	11.7 (1.09)	0.13
Patient-level	14	25
Summary-level	1	51
Umifenovir
Total	10	13	1.3%	10.9 (7.78)	2.16
Patient-level	10	13
Summary-level	0	0
Oseltamivir
Total	10	10	1.1%	19.8 (10.62)	3.36
Patient-level	10	10
Summary-level	0	0
Immunostimulants
Interferon-α/β
Total	14	107	6.1%	9.9 (2.65)	0.26
Patient-level	12	32
Summary-level	2	75
Corticosteroids for systemic use
Methylprednisolone
Total	12	13	3.1%	14.2 (6.69)	1.86
Patient-level	12	13
Summary-level	0	0
Antibacterials for systemic use
Moxifloxacin
Total	10	10	1.7%	16.2 (8.6)	2.73
Patient-level	10	10
Summary-level	0	0